Evidence map›Paper›PMID 29707155›Full record

ArticleOncotarget2018

Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas.

Francesco Vasuri, Silvia Fittipaldi, Vanessa De Pace, Laura Gramantieri, Valentina Bertuzzo, Matteo Cescon, Antonio D Pinna, Michelangelo Fiorentino, Antonia D'Errico, Matteo Ravaioli

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. High expression of IGF2-derived intronic miR-483 predicts outcome in hepatoblastoma.Cancer biomarkers : section A of Disease markers · 2020
    Observational
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Francesco VasuriInstitute of Oncology and Transplant Pathology, Department of Experimental Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Silvia FittipaldiInstitute of Oncology and Transplant Pathology, Department of Experimental Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Vanessa De PaceUnit of General Surgery and Transplantation, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Laura GramantieriInternal Medicine, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Valentina BertuzzoUnit of General Surgery and Transplantation, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Matteo CesconUnit of General Surgery and Transplantation, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Antonio D PinnaUnit of General Surgery and Transplantation, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Michelangelo FiorentinoInstitute of Oncology and Transplant Pathology, Department of Experimental Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Antonia D'ErricoInstitute of Oncology and Transplant Pathology, Department of Experimental Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Matteo RavaioliUnit of General Surgery and Transplantation, Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Policlinico S.Orsola-Malpighi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The choice of surgical treatment for hepatocellular carcinoma (HCC) depends on several prognostic variables, among which histological features, like microvascular invasion and tumor grade, are well established. This study aims to identify the tissue miRNAs predictive of recurrence after liver resection in "histologically advanced" HCC. We selected 54 patients: 15 retrospective resected patients without recurrence (group A), 19 retrospective resected patients with HCC recurrence (group B), and 20 prospective patients (group C), with 4 recurrence cases. All selected HCC were "histologically advanced" (high Edmondson grade and/or presence of microvascular invasion). A wide spectrum of miRNAs was studied with TaqMan Human microRNA Arrays; qRT-PCR assays were used to validate results on selected miRNAs; immunohistochemistry for IGF2 was applied to study the mechanism of miR-483-3p. As a result, a significant differential expression between group A and B was found for 255 miRNAs. Among them we selected miR-483-3p and miR-548e (P<0.001). As a single variable (group C), HCC with miR-483-3p downregulation (mean fold increase 0.21) had 44.4% of recurrence cases; HCC with miR-483-3p upregulation (mean fold increase 5.94) showed no recurrence cases (P=0.011). At immunohistochemistry (group C), the HCC with loss of cytoplasmic IGF2 expression showed a down-regulation of miR-483-3p (fold increase 0.57). In conclusion, in patients with "histologically advanced" HCC, the analysis of specific tissue miRNAs (particularly miR-483-3p) could help identify the recurrence risk and choose which treatment algorithm to implement (follow-up, resection or transplantation). This could have an important impact on patient survival and transplantation outcome, improving organ allocation.

Indexed as

hepatocellular carcinomaIGF2liver resectionmiRNAtumor recurrence

Identifiers

PMID29707155
PMCPMC5915163
OpenAlexW2795670783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.